Systemic Adverse Effects After Osteopathic Treatment and Vitamin C
NCT ID: NCT06102577
Last Updated: 2023-10-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
99 participants
INTERVENTIONAL
2021-11-01
2023-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
• Check if there is a relationship between taking vitamin C and the reduction in the appearance of systemic adverse effects after osteopathic treatment (24-72 hours) First-visit patients, at the end of treatment, are asked to enter the study. If they accept, they are administered 1g. of vitamin C, or 1g. placebo or nothing.
If there is a comparison group: Researchers will compare placebo group, control group and intervention group to see if there is a relationship between taking vitamin C and the appearance of systemic adverse effects\].
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hypovitaminosis C Prevalence and Risk Factors in an Acute Geriatric Unit
NCT05668663
The Effect of Vitamin C on Wound Healing In Mandibular Fracture Patients
NCT03938584
Vitamin C 4 Care Homes
NCT05122481
Effectiveness of Ascorbic Acid and Tocopherol for Depression in Elderly.
NCT02793648
Inter-relationship Between Vitamin D Requirements and Calcium Intake in Older Adults
NCT01990872
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objective Check if there is a relationship between taking vitamin C and the reduction in the appearance of systemic adverse effects after osteopathic treatment (24-72 hours).
Design Triple-blind randomized clinical trial, where one group was given 1g of vitamin C, another group was given 1g of placebo and the third group was given nothing. From April 1 to May 30, 2022, patients without food allergies or intolerances were recruited. The patients were randomly assigned to the study groups and neither the patient, nor the therapist, nor the person in charge of collecting the data was aware of which group each patient belonged to. Adverse reactions were classified in relation to pain and fatigue. Data collection was carried out through WhatsApp messages to the patients 72 hours after receiving the treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1gr. Vitamine C
Take 1g. of vitamin C at the end of an osteopathic manual treatment
1gr. Vitamine C
Take 1g. of vitamin C at the end of an osteopathic manual treatment
1gr.Placebo
Take 1g. of placebo at the end of an osteopathic manual treatment
1gr Placebo
ake 1g. of placebo at the end of an osteopathic manual treatment
control group
control
control group
control
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
1gr. Vitamine C
Take 1g. of vitamin C at the end of an osteopathic manual treatment
1gr Placebo
ake 1g. of placebo at the end of an osteopathic manual treatment
control group
control
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* of legal age,
* without food allergies or intelorenacies
* the ability to receive and send messages via WhatsApp.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Medicina Esportiva i Osteopatia, Spain
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rafael Merino Solis
Dr. Rafael Merino Solis MD.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Rafael Merino Solis, MD
Role: PRINCIPAL_INVESTIGATOR
CMosteoesport
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Medicina Esportiva i Osteopatia
Mollet del Vallès, Barcelona, Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OMT and Vit.C
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.